Viggo F. I. Van Tendeloo - Search Results

Year	Number of Results
2002	1
2003	1
2004	1
2005	1
2006	4
2007	3
2008	5
2009	5
2010	2
2011	4
2012	4
2013	1
2014	5
2015	3
2016	1
2017	1
2018	2
2019	1
2020	1
2021	1
2024	0

1

Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.

Versteven M, Van den Bergh JMJ, Marcq E, Smits ELJ, Van Tendeloo VFI, Hobo W, Lion E. Versteven M, et al. Among authors: van tendeloo vfi. Front Immunol. 2018 Mar 1;9:394. doi: 10.3389/fimmu.2018.00394. eCollection 2018. Front Immunol. 2018. PMID: 29599770 Free PMC article. Review.

2

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.

Timmers M, Roex G, Wang Y, Campillo-Davo D, Van Tendeloo VFI, Chu Y, Berneman ZN, Luo F, Van Acker HH, Anguille S. Timmers M, et al. Among authors: van tendeloo vfi. Front Immunol. 2019 Jul 16;10:1613. doi: 10.3389/fimmu.2019.01613. eCollection 2019. Front Immunol. 2019. PMID: 31379824 Free PMC article. Review.

3

Regulatory T cells and human disease.

Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN. Cools N, et al. Among authors: van tendeloo vf. Clin Dev Immunol. 2007;2007:89195. doi: 10.1155/2007/89195. Clin Dev Immunol. 2007. PMID: 18317534 Free PMC article. Review.

4

Dendritic cell-based cancer gene therapy.

Smits EL, Anguille S, Cools N, Berneman ZN, Van Tendeloo VF. Smits EL, et al. Among authors: van tendeloo vf. Hum Gene Ther. 2009 Oct;20(10):1106-18. doi: 10.1089/hum.2009.145. Hum Gene Ther. 2009. PMID: 19656053 Review.

5

Immunotherapy of hematological malignancies using dendritic cells.

Van de Velde AL, Berneman ZN, Van Tendeloo VF. Van de Velde AL, et al. Among authors: van tendeloo vf. Bull Cancer. 2008 Mar;95(3):320-6. doi: 10.1684/bdc.2008.0602. Bull Cancer. 2008. PMID: 18390412 Free article. Review.

6

NK cells: key to success of DC-based cancer vaccines?

Lion E, Smits EL, Berneman ZN, Van Tendeloo VF. Lion E, et al. Among authors: van tendeloo vf. Oncologist. 2012;17(10):1256-70. doi: 10.1634/theoncologist.2011-0122. Epub 2012 Aug 20. Oncologist. 2012. PMID: 22907975 Free PMC article. Review.

7

The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy.

Campillo-Davo D, De Laere M, Roex G, Versteven M, Flumens D, Berneman ZN, Van Tendeloo VFI, Anguille S, Lion E. Campillo-Davo D, et al. Among authors: van tendeloo vfi. Pharmaceutics. 2021 Mar 16;13(3):396. doi: 10.3390/pharmaceutics13030396. Pharmaceutics. 2021. PMID: 33809779 Free PMC article. Review.

8

The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.

Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. Smits EL, et al. Among authors: van tendeloo vf. Oncologist. 2008 Aug;13(8):859-75. doi: 10.1634/theoncologist.2008-0097. Epub 2008 Aug 13. Oncologist. 2008. PMID: 18701762 Free article. Review.

9

Dendritic cell therapy of cancer: can it fulfill its promise?

Vermorken JB, Van Tendeloo VF. Vermorken JB, et al. Among authors: van tendeloo vf. Expert Rev Anticancer Ther. 2003 Feb;3(1):1-3. doi: 10.1586/14737140.3.1.1. Expert Rev Anticancer Ther. 2003. PMID: 12597344 Review. No abstract available.

10

mRNA-based gene transfer as a tool for gene and cell therapy.

Van Tendeloo VF, Ponsaerts P, Berneman ZN. Van Tendeloo VF, et al. Curr Opin Mol Ther. 2007 Oct;9(5):423-31. Curr Opin Mol Ther. 2007. PMID: 17932806 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

42 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year